Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J.A. de Jonge, Jean Yves Blay, Antoîne Italiano, Kan Yonemori, Daniel C. Cho, Filip De Vos, Philippe Moreau, Elena Élez, Jan H.M. Schellens, Christoph Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung‐Jue Bang (2023). Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. , 29(5), DOI: https://doi.org/10.1038/s41591-023-02321-8.
Article20 days agoAbstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. De Jonge, Jean Yves Blay, Antoîne Italiano, Kan Yonemori, Daniel C. Cho, Filip YFL de Vos, Philippe Moreau, Elena Élez, Jan H.M. Schellens, Christoph Zielinski, Suman Redhu, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung‐Jue Bang (2023). Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study. , 83(8_Supplement), DOI: https://doi.org/10.1158/1538-7445.am2023-ct083.
Article19 days agoAbstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)
Vivek Subbiah, Alexander Stein, Martin J. van den Bent, Antje Wick, Filip De Vos, Nikolas von Bubnoff, Myra E. van Linde, Albert Lai, Gerald W. Prager, Mario Campone, Angelica Fasolo, José A. López-Martín, Tae Min Kim, Ralf‐Dieter Hofheinz, Jean Yves Blay, Daniel C. Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Patrick Y. Wen (2021). Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG). , 81(13_Supplement), DOI: https://doi.org/10.1158/1538-7445.am2021-ct025.
Article15 days ago